Pfizer’s main weakness lies in its strong reliance on the blockbuster portfolio that generates almost a half of the overall sales. Another weakness is the negative brand image due to involvement in largest healthcare fraud of marketing its drug illegally.
Also, discontinuation of products in the latter stages of development.
Weakness of Pfizer
Inadequate infrastructure for fermentation-based drug remedies and effluent treatment plants.
Limited emission right.
Overdependence on blockbuster drugs.
Lack of or inadequate subsidies and fiscal incentives for the industry.
Marketing with other companies and merging with other pharmaceuticals can halter its global popularity.
Tough competition from other major pharma brands means limited scope for market share growth.